Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended | |
Sep. 30, 2013 | Oct. 31, 2013 | |
Document and Entity Information [Abstract] | ' | ' |
Entity Registrant Name | 'Medizone International Inc | ' |
Document Type | '10-Q | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Common Stock, Shares Outstanding | ' | 317,612,639 |
Amendment Flag | 'false | ' |
Entity Central Index Key | '0000753772 | ' |
Entity Current Reporting Status | 'Yes | ' |
Entity Voluntary Filers | 'No | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Well-known Seasoned Issuer | 'No | ' |
Document Period End Date | 30-Sep-13 | ' |
Document Fiscal Year Focus | '2013 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (Unaudited) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | |
Current Assets: | ' | ' | |
Cash | $140,774 | $12,456 | [1] |
Inventory | 0 | 45,548 | [1] |
Prepaid expenses | 325,674 | 118,344 | [1] |
Total Current Assets | 466,448 | 176,348 | [1] |
Property and Equipment, net | 8,162 | 5,964 | [1] |
Other Assets: | ' | ' | |
Trademark and patents, net | 212,808 | 208,490 | [1] |
Lease deposit | 4,272 | 4,272 | [1] |
Total Other Assets | 217,080 | 212,762 | [1] |
Total Assets | 691,690 | 395,074 | [1] |
Current Liabilities: | ' | ' | |
Accounts payable | 438,606 | 453,885 | [1] |
Accounts payable – related parties | 234,572 | 234,572 | [1] |
Accrued expenses | 504,632 | 487,690 | [1] |
Accrued expenses – related parties | 1,928,659 | 1,975,084 | [1] |
Customer deposits | 30,000 | 34,554 | [1] |
Notes payable | 310,334 | 298,536 | [1] |
Total Current Liabilities | 3,446,803 | 3,484,321 | [1] |
Other Payables | 224,852 | 224,852 | [1] |
Total Liabilities | 3,671,655 | 3,709,173 | [1] |
Commitments and Contingencies (Notes 4 and 5) | ' | ' | [1] |
Stockholders’ Deficit: | ' | ' | |
Preferred stock, $0.00001 par value; 50,000,000 shares authorized, no shares issued or outstanding | 0 | 0 | [1] |
Common stock, $0.001 par value, 395,000,000 shares authorized, 315,662,639 and 288,771,227 shares issued and outstanding, respectively | 315,663 | 288,771 | [1] |
Additional paid-in capital | 27,771,790 | 26,506,566 | [1] |
Accumulated other comprehensive loss | -24,530 | -24,444 | [1] |
Accumulated deficit | -31,042,888 | -30,084,992 | [1] |
Total Stockholders' Deficit | -2,979,965 | -3,314,099 | [1] |
Total Liabilities and Stockholders’ Deficit | $691,690 | $395,074 | [1] |
[1] | The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date. |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | |
Preferred stock, shares authorized (in Shares) | 50,000,000 | 50,000,000 | [1] |
Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | [1] |
Preferred stock, shares issued (in Shares) | 0 | 0 | [1] |
Preferred stock, shares outstanding (in Shares) | 0 | 0 | [1] |
Common stock, shares authorized (in Shares) | 395,000,000 | 395,000,000 | [1] |
Common stock, par value (in Dollars per share) | $0.00 | $0.00 | [1] |
Common stock, shares issued (in Shares) | 315,662,639 | 288,771,227 | [1] |
Common stock, shares outstanding (in Shares) | 315,662,639 | 288,771,227 | [1] |
[1] | The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date. |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Revenues | $0 | $150,000 | $379,554 | $150,000 |
Operating Expenses: | ' | ' | ' | ' |
Cost of revenues | 0 | 86,725 | 239,436 | 86,725 |
General and administrative | 263,385 | 932,872 | 856,664 | 2,514,018 |
Research and development | 64,761 | 187,126 | 184,643 | 546,054 |
Depreciation and amortization | 11,420 | 9,561 | 37,827 | 26,488 |
Total Operating Expenses | 339,566 | 1,216,284 | 1,318,570 | 3,173,285 |
Loss from Operations | -339,566 | -1,066,284 | -939,016 | -3,023,285 |
Interest Expense | -6,125 | -6,097 | -18,880 | -18,445 |
Net Loss | -345,691 | -1,072,381 | -957,896 | -3,041,730 |
Other Comprehensive Loss: | ' | ' | ' | ' |
Gain (loss) on foreign currency translation | 1,282 | 957 | -86 | -1,589 |
Total Comprehensive Loss | ($344,409) | ($1,071,424) | ($957,982) | ($3,043,319) |
Basic and Diluted Net Loss per Common Share (in Dollars per share) | $0 | $0 | $0 | ($0.01) |
Weighted Average Number of Common Shares Outstanding (in Shares) | 312,649,052 | 282,697,797 | 304,549,347 | 280,103,399 |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | ||
Cash Flows from Operating Activities: | ' | ' | |
Net loss | ($957,896) | ($3,041,730) | |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' | |
Depreciation and amortization | 37,576 | 26,416 | |
Value of stock options granted | 131,866 | 1,931,325 | |
Changes in operating assets and liabilities: | ' | ' | |
Prepaid expenses | -144,343 | 28,724 | |
Inventory | 45,548 | -91,547 | |
Customer deposits | -4,554 | 10,000 | |
Accounts payable (includes related parties) | -15,280 | 59,931 | |
Accrued expenses (includes related parties) | -29,483 | 26,611 | |
Net Cash Used in Operating Activities | -936,566 | -1,050,270 | |
Cash Flows from Investing Activities: | ' | ' | |
Purchase of trademark and patents | -36,551 | -89,118 | |
Purchase of property and equipment | -7,540 | -3,148 | |
Net Cash Used in Investing Activities | -44,091 | -92,266 | |
Cash Flows from Financing Activities: | ' | ' | |
Principal payments on notes payable | -51,189 | -26,449 | |
Issuance of common stock for cash | 1,160,250 | 1,284,935 | |
Net Cash Provided by Financing Activities | 1,109,061 | 1,258,486 | |
Effect of Foreign Currency Exchange Rates | -86 | -1,589 | |
Net increase in cash | 128,318 | 114,361 | |
Cash as of beginning of the period | 12,456 | [1] | 129,759 |
Cash as of end of the period | 140,774 | 244,120 | |
SUPPLEMENTAL CASH FLOW INFORMATION: | ' | ' | |
Cash Paid for Interest | 697 | 702 | |
NON-CASH FINANCING ACTIVITIES: | ' | ' | |
Financing of insurance policies | $62,987 | $54,678 | |
[1] | The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date. |
NOTE_1_BASIS_OF_PRESENTATION
NOTE 1 BASIS OF PRESENTATION | 9 Months Ended |
Sep. 30, 2013 | |
Disclosure Text Block [Abstract] | ' |
Business Description and Basis of Presentation [Text Block] | ' |
NOTE 1 BASIS OF PRESENTATION | |
The financial information included herein is unaudited and has been prepared consistent with United States generally accepted accounting principles (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all information and notes required by US GAAP for complete financial statements. These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2012. In the opinion of management, these financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary to provide a fair presentation for the interim periods. The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year. | |
NOTE_2_CANADIAN_FOUNDATION_FOR
NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH | 9 Months Ended |
Sep. 30, 2013 | |
Disclosure Text Block [Abstract] | ' |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | ' |
NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH | |
In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible. | |
US GAAP requires a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity may be considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate the VIE’s financial statements with its own. The Company determined that CFGH meets the requirements of a VIE effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial position and operations of CFGH have been consolidated with the Company for all periods presented. | |
NOTE_3_BASIC_AND_DILUTED_NET_L
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Earnings Per Share [Abstract] | ' | ||||||||
Earnings Per Share [Text Block] | ' | ||||||||
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE | |||||||||
The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows: | |||||||||
For the Three Months Ended September 30, | |||||||||
2013 | 2012 | ||||||||
Numerator: Net loss | $ | (345,691 | ) | $ | (1,072,381 | ) | |||
Denominator: Weighted average number of common shares outstanding | 312,649,052 | 282,697,797 | |||||||
Basic and diluted net loss per common share | $ | (0.00 | ) | $ | (0.00 | ) | |||
For the Nine Months Ended September 30, | |||||||||
2013 | 2012 | ||||||||
Numerator: Net loss | $ | (957,896 | ) | $ | (3,041,730 | ) | |||
Denominator: Weighted average number of common shares outstanding | 304,549,347 | 280,103,399 | |||||||
Basic and diluted net loss per common share | $ | (0.00 | ) | $ | (0.01 | ) | |||
Common stock equivalents, consisting of options to purchase a total of 15,150,00 shares of common stock, have not been included in the calculation as their effect is antidilutive for the periods presented. | |||||||||
NOTE_4_GOING_CONCERN
NOTE 4 GOING CONCERN | 9 Months Ended |
Sep. 30, 2013 | |
Going Concern Disclosure [Abstract] | ' |
Going Concern Disclosure [Text Block] | ' |
NOTE 4 GOING CONCERN | |
The Company’s consolidated financial statements are prepared using US GAAP applicable to a going concern which contemplates the realization of assets and settlement of liabilities in the normal course of business. The Company has incurred significant losses from its inception through September 30, 2013, which have resulted in an accumulated deficit of $31,042,888 as of September 30, 2013. The Company does not have funds sufficient to cover its operating costs for the next 12 months, has a working capital deficit of $2,980,355, and has relied on debt and equity financing to sustain its operations. Accordingly, there is substantial doubt about its ability to continue as a going concern. | |
Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and ultimately, upon the Company’s attaining profitable operations. The Company will require substantial, additional funds to complete the development of its products, perform hospital beta testing and fund additional losses, until future revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining additional funding, it may be forced to substantially reduce or cease operations. | |
The Company believes that it will need approximately $2,000,000 over the next 12 months for continuing research expenses, marketing, and related activities, as well as for general corporate purposes, including expanded manufacturing and sales. | |
During 2012, the Company raised a total of $1,420,793 through the sale of 16,729,278 shares of common stock at prices ranging from $0.05 to $0.165 per share, which funds have been used pay current obligations and to pay for the initial costs of development for its hospital disinfection system. During the nine months ended September 30, 2013, the Company raised a total of $1,160,250 through the sale of 26,891,412 shares of common stock at prices ranging from $0.03 to $0.06 per share. The Company believes it will be able to raise additional funds from some of the same investors who have purchased shares from 2009 to 2013, although there is no guarantee that these investors will purchase additional shares. Certain of these investors have orally committed to continue to fund the Company’s projects on a monthly basis. | |
Continuing as a going concern is dependent on the Company’s ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of these uncertainties. | |
NOTE_5_COMMITMENTS_AND_CONTING
NOTE 5 COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Sep. 30, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Commitments and Contingencies Disclosure [Text Block] | ' |
NOTE 5 COMMITMENTS AND CONTINGENCIES | |
The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position or results of operations. | |
Litigation | |
Rakas vs. Medizone International, Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement. In September 2001, the parties agreed to settle the matter for $25,000. The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002. On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties. The Company has been unable to post the required bond amount as of the date of this report. Therefore, the Company has recorded a liability (included in accounts payable) for the original default judgment of $143,000, plus fees totaling $21,308, as of September 30, 2013 and December 31, 2012. The Company intends to contest the judgment when it is able to do so in the future. | |
Other Payables | |
As of September 30, 2013 and December 31, 2012, the Company has recorded other payables totaling $224,852 for past due amounts owing for which the Company has not received invoices or demands for over 10 years. Although management of the Company does not believe that the amounts will be paid, the amounts are being recorded as other payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired. | |
Operating Leases | |
The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform. The lease term expired on June 30, 2012, and is now month-to-month with a monthly lease payment of $1,375 Canadian dollars (“CD”) plus the applicable goods and services tax (“GST”). A lease for a second laboratory space for full scale room testing and a storage space also expired on June 30, 2012, and is now month-to-month with a monthly lease payment of $1,375 CD and $475 CD, respectively, plus the applicable GST. | |
The Company entered into a corporate office lease effective from January 1, 2012 through December 31, 2012 with monthly payments of $2,100. The lease term was extended for another year, through December 31, 2013, with monthly lease payments increasing from $2,100 to $2,200. | |
NOTE_6_COMMON_STOCK_OPTIONS
NOTE 6 COMMON STOCK OPTIONS | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Disclosure Text Block Supplement [Abstract] | ' | ||||||||
Shareholders' Equity and Share-based Payments [Text Block] | ' | ||||||||
NOTE 6 COMMON STOCK OPTIONS | |||||||||
On August 26, 2009, the Company granted options for the purchase of 1,500,000 shares of common stock to an outside consultant for services rendered, with an exercise price of $0.10 per share, exercisable for up to five years, but including vesting provisions as follows: (i) options for 500,000 shares vested immediately on the date of grant, (ii) options for 500,000 shares vested in September 2012, the date certified by the Company as the date its hospital disinfection program completed its beta-testing, and (iii) the remaining options for 500,000 shares will vest on the date certified by the Company as the date that its disinfection process has been commercialized and a minimum of 50 units or devices have been sold to third parties. During the three months ended September 30, 2012, options for 500,000 shares valued at $48,699 vested, and were recorded as part of general and administrative expenses. As of September 30, 2013, options for 500,000 shares had not yet vested. | |||||||||
In July 2010, the Company granted options for the purchase of 3,500,000 shares of common stock (of which 250,000 were cancelled in 2011) to certain board members and employees of the Company for services rendered. These options are exercisable for five years from the date of grant at $0.20 per share, and the remaining options vested when the Company achieved commercial sales during the third quarter of 2012, resulting in $659,822 being recorded as part of general and administrative expense. | |||||||||
In September 2010, the Company granted options for the purchase of 250,000 shares of common stock to a consultant in connection with extending his consulting agreement with the Company through September 2011. These options are exercisable at $0.275 per share for five years from the date of grant and vested when the Company achieved commercial sales during the third quarter of 2012, resulting in $65,067 being recorded as part of general and administrative expense. | |||||||||
In February 2012, the Board of Directors approved the 2012 Equity Incentive Award Plan and authorized up to 10,000,000 shares of common stock to be available for awards under the Plan. On February 21, 2012, each of four directors of the Company was awarded stock options for the purchase of 1,000,000 shares of common stock, exercisable at a price of $0.23 per share, which was the fair value of the common stock based on the price of the Company’s common stock reported on the OTC Bulletin Board on the date of grant. In addition, certain officers, consultants and employees of the Company were awarded options for the purchase of an aggregate 1,050,000 shares of common stock at an exercise price of $0.23 per share. The value of these options granted, totaling $1,057,600, was recognized as expense during the nine months ended September 30, 2012 as each of the options granted was fully vested on the date of grant. | |||||||||
In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for services. Options for 550,000 shares have vested and the remaining options will vest on the date certified by the Company as the date that the other milestones are achieved. The options have an exercise price of $0.15 per share, and are exercisable for up to five years. The value of these options granted was $153,997 in connection with which the Company recognized $69,300 during the nine months ended September 30, 2013. As of September 30, 2013, options for the purchase of 550,000 shares have vested. | |||||||||
In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for medical consulting support services already performed and to be performed in the future. The options have an exercise price of $0.17 per share, and are exercisable for up to five years. The value of the options vested upon grant was $149,460, of which the Company recognized $49,322 and $100,138 during the nine months ended September 30, 2013 and 2012, respectively. As of September 30, 2013, all of the milestones were achieved and all of the shares vested. | |||||||||
In August 2012, the Company granted options for the purchase of 2,500,000 shares of common stock to three individuals in connection with the purchase of restricted stock, exercisable at a price of $0.05 per share. No expense was recorded for these options as the value associated with these options was recorded as part of the stock transactions. These options held a six-month term and have expired without being exercised. | |||||||||
In August 2013, the Company granted options for the purchase of 250,000 shares of common stock to a consultant. These options are exercisable at $0.10 per share for five years from the date of grant with 50,000 shares vesting immediately and the other 200,000 upon the achievement of certain milestones. The value of these options granted was $22,075 of which the Company recognized $4,415 which was recorded as part of general and administrative expense during the three months ended September 30, 2013. | |||||||||
In August 2013, the Company granted options for the purchase of 100,000 shares of common stock to an employee for services already performed. The options have an exercise price of $0.10 per share, and are exercisable for up to five years. The value of the options vested upon grant was $8,830 which the Company recorded as part of general and administrative expense during the three months ended September 30, 2013. | |||||||||
The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions: | |||||||||
Risk-free interest rate | 0.75 | % | to | 1.66 | % | ||||
Expected life | 5 years | ||||||||
Expected volatility | 138.3 | % | to | 148.9 | % | ||||
Dividend yield | 0 | % | |||||||
A summary of the status of the Company’s outstanding options as of September 30, 2013, and for the nine months then ended, is presented below: | |||||||||
Shares | Weighted Average | ||||||||
Exercise Price | |||||||||
Outstanding, beginning of the period | 17,300,000 | $ | 0.17 | ||||||
Granted | 350,000 | 0.1 | |||||||
Expired/Canceled | (2,500,000 | ) | 0.05 | ||||||
Exercised | - | - | |||||||
Outstanding, end of the period | 15,150,000 | 0.19 | |||||||
Exercisable | 14,000,000 | $ | 0.19 | ||||||
The Company estimates the fair value of each stock award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes option-pricing model is zero. Expense of $131,866 and $1,931,325 related to stock options was recorded for the nine months ended September 30, 2013 and 2012, respectively. As of September 30, 2013, the Company had various unvested outstanding options with related unrecognized expense of $135,657. The Company will recognize this expense as these options vest over their remaining lives, which range from 11 to 59 months. | |||||||||
NOTE_7_STOCK_TRANSACTIONS_AND_
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS | 9 Months Ended |
Sep. 30, 2013 | |
Stockholders' Equity Note [Abstract] | ' |
Stockholders' Equity Note Disclosure [Text Block] | ' |
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS | |
During August and September 2013, the Company sold 5,000,000 restricted shares of common stock to eight accredited investors for cash proceeds totaling $300,000, or $0.06 per share. | |
During May and June 2013, the Company sold 5,863,636 restricted shares of common stock to 11 accredited investors for cash proceeds totaling $322,500, or $0.055 per share. | |
During April and May 2013, the Company sold 3,794,444 restricted shares of common stock to six accredited investors for cash proceeds totaling $170,750, or $0.045 per share. | |
During January, February, and March 2013, the Company sold an aggregate of 12,233,332 restricted shares of common stock to 12 accredited investors for cash proceeds totaling $367,000, or $0.03 per share. | |
During January and February 2012, the Company sold an aggregate of 6,653,000 restricted shares of common stock to 30 accredited investors for cash proceeds of $665,300, or $0.10 per share. | |
During July, August and September 2012, the Company sold an aggregate of 5,233,333 restricted shares of common stock to 11 accredited investors for cash proceeds of $296,500 at prices ranging from $0.05 to $0.09 per share. | |
Stock Purchase Agreement | |
In November 2010, the Company entered into a two-year Stock Purchase Agreement with Mammoth providing for the Equity Line. The Stock Purchase Agreement provided that, upon the terms and subject to the conditions in the Stock Purchase Agreement, Mammoth committed to purchase up to $10,000,000 of shares of common stock over the term of the Stock Purchase Agreement under certain specified conditions and limitations. Mammoth was barred from purchasing any shares of the Company’s common stock which, when aggregated with all other shares of common stock then beneficially owned by Mammoth, would result in the beneficial ownership by Mammoth of more than 4.9% of the then outstanding shares of the Company’s common stock. These maximum share and beneficial ownership limitations could not be waived by the parties. | |
Under the terms of the Stock Purchase Agreement, the Company had the opportunity for a 24-month period, commencing on the date on which the Securities and Exchange Commission (“SEC”) first declared effective the registration statement filed in connection with the resale of shares issued under the Equity Line, to require Mammoth to purchase up to $10,000,000 in shares of common stock. For each share of common stock purchased under the Stock Purchase Agreement, Mammoth would pay a purchase price equal to 75% of the lowest closing bid price during the five consecutive trading-day period (the “Draw Down Pricing Period”) preceding the date a draw down notice (the “Draw Down Notice”) was delivered by the Company to Mammoth (the “Draw Down Date”) in a manner provided by the Stock Purchase Agreement. The SEC declared the registration statement effective on January 25, 2011. The Stock Purchase Agreement and Equity Line terminated on January 25, 2013. | |
Wood Wyant Canada | |
In April 2013, the Company and Wood Wyant Canada (“Wood Wyant”), a subsidiary of Sanimarc Group, announced that Wood Wyant had become a National Hospital Distributor of AsepticSure® in Canada. Wood Wyant serves Canada from 16 locations across all 10 provinces, providing both sales and service to the hospital market. The Company delivered an initial order for five systems to Wood Wyant for proceeds totaling $375,000. The Company has six more systems in production. | |
ADA Innovations | |
In December 2010, the Company reached a Services Agreement with ADA Innovations (“ADA”) for final development and production manufacturing of portable versions (the “Projects”) of the Company’s AsepticSure® disinfection systems. A contract containing the terms of the agreement and detailed development plan was executed by the parties in January 2011 and amended in January 2012. Any and all notes, reports, information, inventions, sketches, plans, concepts, data or other works created by ADA on its behalf under the Services Agreement will be the sole and exclusive property of the Company. | |
The term of the Services Agreement continues until the completion of the development and design projects contemplated by the Services Agreement, unless terminated earlier by either party in accordance with specific notices as outlined in the Services Agreement. Deliverables include: (1) the pre-production prototype designed and manufactured to the Company’s specifications, (2) design and device content compliant with all North America, Europe and United Kingdom regulatory and licensing agency regulations, (3) a soft launch program managed by ADA and the Company, intended to be followed by increased production, and (4) additional outsourced macro-manufacturing capacity as required, supervised by the parties. The Company paid ADA as services were provided and were completed by December 31, 2012. During the three and nine months ended September 30, 2012, the Company incurred expenses totaling approximately $49,000 and $157,000, respectively, for services provided under the Services Agreement, which expenses have been included in research and development expense. No expenses under this contract were incurred during the three and nine months ended September 30, 2013. ADA’s role as developer of the production AsepticSure® system is now complete. ADA remains available to the Company on a limited basis as a consultant. | |
NOTE_8_ACCOUNTS_PAYABLE_RELATE
NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES | 9 Months Ended |
Sep. 30, 2013 | |
Related Party Transactions [Abstract] | ' |
Related Party Transactions Disclosure [Text Block] | ' |
NOTE 8 ACCOUNTS PAYABLE – RELATED PARTIES | |
As of September 30, 2013 and December 31, 2012, the Company had payables of $234,572, owed to certain consultants for services rendered in prior years. These consultants are stockholders of the Company and therefore have been classified as related parties. | |
NOTE_9_SUBSEQUENT_EVENTS
NOTE 9 SUBSEQUENT EVENTS | 9 Months Ended |
Sep. 30, 2013 | |
Subsequent Events [Abstract] | ' |
Subsequent Events [Text Block] | ' |
NOTE 9 SUBSEQUENT EVENTS | |
The Company has evaluated events subsequent to September 30, 2013 for potential accounting or disclosure in the accompanying financial statements, noting the following. During October 2013, the Company sold 1,950,000 restricted shares of common stock to 5 accredited investors for cash proceeds totaling $97,500, or $0.05 per share. | |
NOTE_3_BASIC_AND_DILUTED_NET_L1
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Tables) | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Earnings Per Share [Abstract] | ' | ||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | 'The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows: | ||||||||
For the Three Months Ended September 30, | |||||||||
2013 | 2012 | ||||||||
Numerator: Net loss | $ | (345,691 | ) | $ | (1,072,381 | ) | |||
Denominator: Weighted average number of common shares outstanding | 312,649,052 | 282,697,797 | |||||||
Basic and diluted net loss per common share | $ | (0.00 | ) | $ | (0.00 | ) | |||
For the Nine Months Ended September 30, | |||||||||
2013 | 2012 | ||||||||
Numerator: Net loss | $ | (957,896 | ) | $ | (3,041,730 | ) | |||
Denominator: Weighted average number of common shares outstanding | 304,549,347 | 280,103,399 | |||||||
Basic and diluted net loss per common share | $ | (0.00 | ) | $ | (0.01 | ) |
NOTE_6_COMMON_STOCK_OPTIONS_Ta
NOTE 6 COMMON STOCK OPTIONS (Tables) | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Disclosure Text Block Supplement [Abstract] | ' | ||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 'The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions: | ||||||||
Risk-free interest rate | 0.75 | % | to | 1.66 | % | ||||
Expected life | 5 years | ||||||||
Expected volatility | 138.3 | % | to | 148.9 | % | ||||
Dividend yield | 0 | % | |||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | 'A summary of the status of the Company’s outstanding options as of September 30, 2013, and for the nine months then ended, is presented below: | ||||||||
Shares | Weighted Average | ||||||||
Exercise Price | |||||||||
Outstanding, beginning of the period | 17,300,000 | $ | 0.17 | ||||||
Granted | 350,000 | 0.1 | |||||||
Expired/Canceled | (2,500,000 | ) | 0.05 | ||||||
Exercised | - | - | |||||||
Outstanding, end of the period | 15,150,000 | 0.19 | |||||||
Exercisable | 14,000,000 | $ | 0.19 |
NOTE_2_CANADIAN_FOUNDATION_FOR1
NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH (Details) | 9 Months Ended |
Sep. 30, 2013 | |
Disclosure Text Block [Abstract] | ' |
Variable Interest Entity, Qualitative or Quantitative Information, Purpose of VIE | '(1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company's technology to as many in need as possible. |
NOTE_3_BASIC_AND_DILUTED_NET_L2
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) (Equity Option [Member]) | 9 Months Ended |
Sep. 30, 2013 | |
Equity Option [Member] | ' |
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) [Line Items] | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1,515,000 |
NOTE_3_BASIC_AND_DILUTED_NET_L3
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) - Schedule of Earnings Per Share (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Schedule of Earnings Per Share [Abstract] | ' | ' | ' | ' |
Numerator: Net loss (in Dollars) | ($345,691) | ($1,072,381) | ($957,896) | ($3,041,730) |
Denominator: Weighted average number of common shares outstanding | 312,649,052 | 282,697,797 | 304,549,347 | 280,103,399 |
Basic and diluted net loss per common share (in Dollars per share) | $0 | $0 | $0 | ($0.01) |
NOTE_4_GOING_CONCERN_Details
NOTE 4 GOING CONCERN (Details) (USD $) | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2013 | Dec. 31, 2012 | ||
NOTE 4 GOING CONCERN (Details) [Line Items] | ' | ' | |
Retained Earnings (Accumulated Deficit) (in Dollars) | ($31,042,888) | ($30,084,992) | [1] |
Working capital (deficit) (in Dollars) | -2,980,355 | ' | |
Going Concern Note | 'The Company believes that it will need approximately $2,000,000 over the next 12 months for continuing research expenses, marketing, and related activities, as well as for general corporate purposes, including expanded manufacturing and sales. | ' | |
Stock Issued During Period, Value, New Issues (in Dollars) | $1,160,250 | $1,420,793 | |
Stock Issued During Period, Shares, New Issues (in Shares) | 26,891,412 | 16,729,278 | |
Minimum [Member] | ' | ' | |
NOTE 4 GOING CONCERN (Details) [Line Items] | ' | ' | |
Shares Issued, Price Per Share (in Dollars per share) | $0.03 | $0.05 | |
Maximum [Member] | ' | ' | |
NOTE 4 GOING CONCERN (Details) [Line Items] | ' | ' | |
Shares Issued, Price Per Share (in Dollars per share) | $0.06 | $0.17 | |
[1] | The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date. |
NOTE_5_COMMITMENTS_AND_CONTING1
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | |
USD ($) | USD ($) | Default Judgement [Member] | Default Judgement [Member] | Litigation Fees [Member] | Litigation Fees [Member] | Laboratory Storage Space [Member] | Full Scale Room Testing [Member] | Storage Space [Member] | Corporate Offices [Member] | Corporate Offices [Member] | Settlement Amount, September 2001 [Member] | ||
Rakas Litigation [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | CAD | CAD | CAD | USD ($) | USD ($) | Rakas Litigation [Member] | ||||
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |||||||||
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
Litigation Settlement, Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $25,000 | |
Accounts Payable, Current | 438,606 | 453,885 | [1] | 143,000 | 143,000 | 21,308 | 21,308 | ' | ' | ' | ' | ' | ' |
Other Liabilities, Noncurrent | 224,852 | 224,852 | [1] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Operating Leases, Rent Expense, Minimum Rentals (in Dollars) | ' | ' | ' | ' | ' | ' | 1,375 | 1,375 | 475 | 2,200 | 2,100 | ' | |
Operating Leases, Rent Expense, Minimum Rentals | ' | ' | ' | ' | ' | ' | 1,375 | 1,375 | 475 | $2,200 | $2,100 | ' | |
[1] | The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date. |
NOTE_6_COMMON_STOCK_OPTIONS_De
NOTE 6 COMMON STOCK OPTIONS (Details) (USD $) | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | |||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Sep. 30, 2012 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Sep. 30, 2012 | Dec. 31, 2009 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Sep. 30, 2012 | Dec. 31, 2010 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | |
2012 Equity Incentive Award Plan [Member] | 2012 Equity Incentive Award Plan [Member] | 2012 Equity Incentive Award Plan [Member] | 2012 Equity Incentive Award Plan [Member] | 2012 Equity Incentive Award Plan [Member] | 2012 Equity Incentive Award Plan [Member] | 2012 Equity Incentive Award Plan [Member] | 2012 Equity Incentive Award Plan [Member] | 2012 Equity Incentive Award Plan [Member] | Stock Options Issued August 26, 2009 [Member] | Stock Options Issued August 26, 2009 [Member] | Stock Options Issued August 26, 2009 [Member] | Stock Options Issued July 2010 [Member] | Stock Options Issued July 2010 [Member] | Stock Options Issued July 2010 [Member] | Options Granted September 2010 [Member] | Options Granted September 2010 [Member] | Options Granted with Purchase of Restricted Stock, August 2012 [Member] | Options Granted to a Consultant in August 2013 [Member] | Options Granted to Employee for Services in August 2013 [Member] | Minimum [Member] | Maximum [Member] | |||
Options Granted to Directors, February 2012 [Member] | Options Granted to Officers, Consultants and Employees, February 2012 [Member] | Options Granted to Officers, Consultants and Employees, February 2012 [Member] | Options Issued for Distribution Related Services, May 2012 [Member] | Options Issued for Distribution Related Services, May 2012 [Member] | Options Granted for Medical Consulting Support Services, May 2012 [Member] | Options Granted for Medical Consulting Support Services, May 2012 [Member] | Options Granted for Medical Consulting Support Services, May 2012 [Member] | |||||||||||||||||
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | ' | ' | 1,000,000 | ' | 1,050,000 | ' | 1,000,000 | ' | ' | 1,000,000 | ' | ' | 1,500,000 | ' | ' | ' | 3,500,000 | ' | 250,000 | 2,500,000 | 250,000 | 100,000 | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '500,000 shares of common stock to an outside consultant for services rendered, with an exercise price of $0.10 per share, exercisable for up to five years, but including vesting provisions as follows: (i) options for 500,000 shares vested immediately on the date of grant, (ii) options for 500,000 shares vested in September 2012, the date certified by the Company as the date its hospital disinfection program completed its beta-testing, and (iii) the remaining options for 500,000 shares will vest on the date certified by the Company as the date that its disinfection process has been commercialized and a minimum of 50 units or devices have been sold to third parties. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | ' | ' | $0.23 | ' | $0.23 | ' | $0.15 | ' | ' | $0.17 | ' | ' | $0.10 | ' | ' | ' | $0.20 | ' | $0.28 | $0.05 | $0.10 | $0.10 | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | '5 years | ' | ' | '5 years | ' | ' | ' | '5 years | ' | '5 years | '6 months | '5 years | '5 years | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 550,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | 50,000 | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | $149,460 | ' | $48,699 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $8,830 | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 250,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation (in Dollars) | 131,866 | 1,931,325 | ' | 1,057,600 | ' | 69,300 | ' | 49,322 | 100,138 | ' | ' | ' | ' | ' | 659,822 | ' | ' | 65,067 | ' | ' | 4,415 | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of directors issued options | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | ' | ' | ' | ' | ' | ' | 550,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars) | ' | ' | ' | ' | ' | 153,997 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 22,075 | ' | ' | ' |
Number of Investors | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3 | ' | ' | ' | ' |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | $135,657 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '11 months | '59 months |
NOTE_6_COMMON_STOCK_OPTIONS_De1
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options | 9 Months Ended |
Sep. 30, 2013 | |
Schedule of Fair Value Assumptions of Stock Options [Abstract] | ' |
Risk-free interest rate | 1.66% |
Risk-free interest rate | 0.75% |
Expected life | '5 years |
Expected volatility | 138.30% |
Expected volatility | 148.90% |
Dividend yield | 0.00% |
NOTE_6_COMMON_STOCK_OPTIONS_De2
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity (USD $) | 9 Months Ended |
Sep. 30, 2013 | |
Shares [Member] | ' |
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity [Line Items] | ' |
Outstanding, beginning of the period | 17,300,000 |
Granted | 350,000 |
Expired/Canceled | -2,500,000 |
Exercised | 0 |
Outstanding, end of the period | 15,150,000 |
Exercisable | 14,000,000 |
Weighted Average Exercise Price [Member] | ' |
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity [Line Items] | ' |
Outstanding, beginning of the period (in Dollars per share) | 0.17 |
Granted (in Dollars per share) | 0.1 |
Expired/Canceled (in Dollars per share) | 0.05 |
Exercised (in Dollars per share) | 0 |
Outstanding, end of the period (in Dollars per share) | 0.19 |
Exercisable (in Dollars per share) | 0.19 |
NOTE_7_STOCK_TRANSACTIONS_AND_1
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) (USD $) | 9 Months Ended | 12 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2010 | Dec. 31, 2010 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | |
Stock Purchase Agreement [Member] | Stock Purchase Agreement [Member] | Wood Wyant Canada [Member] | ADA Innovations [Member] | ADA Innovations [Member] | ADA Innovations [Member] | ADA Innovations [Member] | Restricted Stock Issued During August and September 2013 [Member] | Restricted Stock Issued During May and June 2013 [Member] | Restricted Stock Issued During April and May 2013 [Member] | Restricted Stock Issued During January, February and March 2013 [Member] | Restricted Stock Issued During January and February 2012 [Member] | Restricted Stock Issued During July, August and September 2012 [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | |||
Maximum [Member] | Restricted Stock Issued During July, August and September 2012 [Member] | Restricted Stock Issued During July, August and September 2012 [Member] | |||||||||||||||||||
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,000,000 | 5,863,636 | 3,794,444 | 12,233,332 | 6,653,000 | 5,233,333 | ' | ' | ' | ' | ' | ' |
Number of Investors | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8 | 11 | 6 | 12 | 30 | 11 | ' | ' | ' | ' | ' | ' |
Proceeds from Issuance or Sale of Equity (in Dollars) | $1,160,250 | $1,284,935 | ' | ' | ' | ' | ' | ' | ' | $300,000 | $322,500 | $170,750 | $367,000 | $665,300 | $296,500 | ' | ' | ' | ' | ' | ' |
Shares Issued, Price Per Share (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.06 | $0.06 | $0.05 | $0.03 | $0.10 | ' | $0.05 | $0.03 | $0.05 | $0.09 | $0.06 | $0.17 |
Stock Repurchase Program, Period in Force | ' | ' | '2 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable | ' | ' | 10,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Equity Method Investment, Ownership Percentage | ' | ' | ' | 4.90% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock purchase agreement, price description | ' | ' | '75% of the lowest closing bid price during the five consecutive trading-day period (the "Draw Down Pricing Period") preceding the date a draw down notice (the "Draw Down Notice") was delivered by the Company to Mammoth (the "Draw Down Date") in a manner provided by the Stock Purchase Agreement | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Supply Commitment, Description | ' | ' | ' | ' | 'The Company delivered an initial order for five systems to Wood Wyant for proceeds totaling $375,000.The Company has six more systems in production. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sales Revenue, Goods, Gross | ' | ' | ' | ' | 375,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Research and Development Expense, Software (Excluding Acquired in Process Cost) | ' | ' | ' | ' | ' | $0 | $49,000 | $0 | $157,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
NOTE_8_ACCOUNTS_PAYABLE_RELATE1
NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | |
Related Party Transactions [Abstract] | ' | ' | |
Accounts Payable, Related Parties, Current | $234,572 | $234,572 | [1] |
[1] | The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date. |
NOTE_9_SUBSEQUENT_EVENTS_Detai
NOTE 9 SUBSEQUENT EVENTS (Details) (USD $) | 9 Months Ended | 1 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | Oct. 31, 2013 | |
Subsequent Event [Member] | |||
NOTE 9 SUBSEQUENT EVENTS (Details) [Line Items] | ' | ' | ' |
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | ' | ' | 1,950,000 |
Number of Investors | ' | ' | 5 |
Proceeds from Issuance or Sale of Equity (in Dollars) | $1,160,250 | $1,284,935 | $97,500 |
Shares Issued, Price Per Share (in Dollars per share) | ' | ' | $0.05 |